Photo of David A Katzka

View Scopus Profile

David A Katzka, MD

  • 8258 Citations
  • 42 Scopus h-Index
1977 …2019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where David A Katzka is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 7 Similar Profiles
Eosinophilic Esophagitis Medicine & Life Sciences
Gastroesophageal Reflux Medicine & Life Sciences
Barrett Esophagus Medicine & Life Sciences
Esophagus Medicine & Life Sciences
Deglutition Disorders Medicine & Life Sciences
Esophageal Achalasia Medicine & Life Sciences
Eosinophilia Medicine & Life Sciences
Endoscopy Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 1988 1993

IONIC CHANNEL REGULATION IN MAMMALIAN VISCERAL MYOCYTES

Katzka, D. A.

National Institutes of Health

7/1/88 → 6/30/93

Project: Research project

Research Output 1977 2019

3 Citations (Scopus)

AGA Clinical Practice Update on Diagnosis and Monitoring of Celiac Disease—Changing Utility of Serology and Histologic Measures: Expert Review

Husby, S., Murray, J. A. & Katzka, D. A., Mar 1 2019, In : Gastroenterology. 156, 4, p. 885-889 5 p.

Research output: Contribution to journal › Review article

Serology
Practice Guidelines
Abdomen
Celiac Disease
Immunoglobulin A
2 Citations (Scopus)

Barrett esophagus length, nodularity, and low-grade dysplasia are predictive of progression to esophageal adenocarcinoma

Solanky, D., Krishnamoorthi, R., Crews, N., Johnson, M., Wang, K. K. N., Wolfsen, H., Fleischer, D., Ramirez, F. C., Katzka, D. A., Buttar, N. S. & Iyer, P. G., May 1 2019, In : Journal of clinical gastroenterology. 53, 5, p. 361-365 5 p.

Research output: Contribution to journal › Article

Barrett Esophagus
Adenocarcinoma
Confidence Intervals
Biopsy
Proportional Hazards Models

Budesonide oral suspension significantly improves eosinophilic esophagitis histology scoring system results: Analyses from a 12-week, phase 2, randomized, placebo-controlled trial

Collins, M. H., Dellon, E. S., Katzka, D. A., Hirano, I., Williams, J. & Lan, L., Jan 1 2019, (Accepted/In press) In : American Journal of Surgical Pathology.

Research output: Contribution to journal › Article

Eosinophilic Esophagitis
Budesonide
Suspensions
Histology
Randomized Controlled Trials

Clinical Features at Baseline Cannot Predict Symptom Response to Placebo in Patients With Eosinophilic Esophagitis

Hirano, I., Dellon, E. S., Collins, M. H., Williams, J., Lan, L. & Katzka, D. A., Sep 1 2019, In : Clinical Gastroenterology and Hepatology. 17, 10, p. 2126-2128.e1

Research output: Contribution to journal › Short survey

Open Access
Eosinophilic Esophagitis
Placebos
Budesonide
Placebo Effect
Immune System Diseases

Corrigendum: Food impaction: Etiology over 35 years and association with eosinophilic esophagitis (Diseases of the Esophagus (doy093) DOI: 10.1093/dote/doy093)

Lenz, C. J., Leggett, C., Katzka, D. A., Larson, J. J., Enders, F. T. & Alexander, J. A., Jan 1 2019, In : Diseases of the Esophagus. 32, 4

Research output: Contribution to journal › Comment/debate

Open Access
National Institute on Aging (U.S.)
Eosinophilic Esophagitis
National Institutes of Health (U.S.)
Esophagus
Epidemiology